Biofourmis Archives - Medical Design Sourcing

GE HealthCare, Biofourmis collab on at-home patient monitoring

GE HealthCare (Nasdaq: GEHC) + announced today that it entered into a collaboration with Biofourmis to enable safe, effective, accessible care in the home.

The two companies paired up to support the patient journey beyond the hospital setting. Their collaboration leverages combined expertise in innovative care-at-home solutions. They say hospital systems face increased costs of care due to workforce shortages, shrinking bed capacity and increasing readmission rates. At-home care can support recovery and safety while potentially reducing fall risks and hospital-acquired infections.

GE HealthCare and BioFourmis want to enable more patients to go home earlier. They hope to offer an alternative to facility-based care , driving healthy behaviors by managing patients remotely. According to a news release, insights from Biofourmis’ FDA-cleared, AI-guided algorithms can help deliver that personalized care.

“…

The biggest medical device VC deals of 2022

Enable Injections, which makes the enFuse device, raised $215 million in January 2022. [Photo courtesy of Enable Injections]

Last year was definitely a slower year for medical device VC deals than the year before.

Biofourmis was the only medical device developer in the 10 largest healthcare VC deals of 2022, according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB).

Because we love devices at Medical Design & Outsourcing, we asked SVB for a ranking of 2022’s largest medical device VC deals after Biofourmis, which raised $325 million in its 2022 series D round. (The year before that, CMR Surgical’s $600 million Series D financing round was the largest medical device VC deal of 2021.)

SVB obliged, once again drawing upon its own proprietary information and data from Pitchbook. The dealmakers include device developers with innovative methods for …

Biofourmis and Chugai Pharma partner to develop an objective measure of pain

Chugai Pharma (TYO:4519) and privately-held remote patient monitoring firm Biofourmis are continuing a collaboration to develop digital technologies to objectively measure and manage pain in endometriosis patients.

In endometriosis, the lining of a uterus grows outside the womb. The condition can also affect the ovaries and fallopian tubes. The disease affects approximately 10% of women of reproductive age. Stabbing pelvic pain is a common endometriosis symptom.

In general, physicians have traditionally relied on subjective measures to gauge pain. One common system, for instance, asks patients to rate their pain on a scale from 0 to 10. The Wong-Baker Faces Pain Rating Scale is similar, including pain scales using even numbers but also incorporating smiling and frowning faces.

While such scales are valuable, they are highly subjective, and patients’ personal experience and cu…

Ranked: The biggest healthcare VC deals of 2022

A company that sends medical teams on house calls had one of the largest venture capital deals of 2022. [Photo courtesy of Dispatch Health]

The $3 billion launch of a biotech focused on cellular rejuvenation was 2022’s largest healthcare venture capital deal in the U.S. and Europe.

That’s according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB), which ranked the deals using its own proprietary information and data from Pitchbook.

The biopharma sector represented three of the 10 largest VC deals. Diagnostics/tools had two deals on the list, taking the No. 2 and 3 spots. The healthtech sector had four deals on the list.

Only one device developer ranked in 2022’s top 10, just like the year before, when CMR Surgical’s $600 million Series D financing round was the fifth-largest deal of 2021. (Healthtech deals dominated the prior-year list by tak…

9 predictions for pharma in 2022

Image courtesy of Pixabay

The pharma industry has been slower to embrace technologies such as AI and digital technology than many less-regulated sectors. The COVID-19 pandemic has changed the equation, forcing pharma companies to become more agile and open-minded in approaching drug discovery and development, including managing evolving clinical trials.

In this article, several experts offered their predictions of the trends that will be most meaningful in 2022.

1. Digital components drive new pharma value

Jaydev Thakkar

In 2022, a growing number of pharmaceutical companies will recognize how their products could deliver significantly improved outcomes with a digital component, predicted Jaydev Thakkar, chief operating officer of Biofourmis, which offers digital therapeutics and care-at-home solutions powered by AI. “This digital component c…